- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03366402
Sub Populations of Immune Cells in Influenza A and B Patients
This study designed to examine changes of immune system cells sub-populations during influenza disease. Several parameters will be examined, such as: amount of sub populations, clinical parameters (body temperature and number of hospitalization days).
The participants are children that are hospitalized in the Laniado hospital pediatric department.
Study Overview
Detailed Description
Background:
In late March and early April 2009 an outbreak of a novel influenza virus designated A/H1N1 influenza (popularly known as swine flu) was reported in Mexico, with subsequent cases observed in many countries, leading to the declaration by the World Health Organization of a worldwide pandemic.
The first case of influenza A/H1N1 in Israel was diagnosed at the end of April 2009 at Laniado Hospital in a young man returning from Mexico.
Influenza A/H1N1 (Swine flu) carries a relatively high morbidity, particularly in young patients. Early identification would enable prompt initiation of therapy, thereby improving outcomes.
In 2009, during the H1N1 pandemic in Israel, a research was conducted in our department of pediatrics. The researchers Sharon et al. (1) have compared a group of 53 children infected with Influenza A H1N1, with a group of 53 children that presented with flu symptoms but were found negative for the virus. This comparison demonstrated a significant reduction in lymphocyte count during the acute phase of the disease (days 1-3) with resolution on day 7 (6-9) as well as reduction in the neutrophil count on day 5 from the onset of high fever with subsequent resolution 2-4 days later (days 7-10). This phenomenon was not observed in the patients that were not infected with the H1N1 virus. Similar results were reported by Cao and co-authors (2) that observed it in both pediatric and adult patients. Lewis at al suggested that the lymphopenia is mainly due to reduction in T cells and to a lesser extent in B cells (3). The lymphopenia typical of influenza A H3N3 during acute illness was shown to be due to a reduction in both T and B cells without alteration in the CD4:CD8 ratio. This is in contrast to the findings of Cao et al. (2) who noted an abnormal CD4:CD8 ratio in half of those who were positive for A H1N1. One of the possible explanations as proposed by Nichols and Collaborators (4) is that early lymphopenia and the later neutropenia in the influenza infected patients may represent migration of these cells from the circulation to the infected respiratory tract as a consequence of infection. Goals of our research To quantify the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
Study methods The subjects of the study were children that were hospitalized at our department with signs and symptoms of flu. The parents or legal guardians of the participants have signed a written consent. At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
Laboratory technique:
Cellular markers were assessed by flow cytometry. Cell staining was performed on single cell suspensions using pre-cooled PBS in 5 ml FACS tubes. Washing steps were performed by centrifugation for 5min, 300 g, 5°C, brake 5 after which supernatants were completely pipetted off and cell pellets (typically containing 0.2-1.0×106 cells) were re-suspended in 100 μl PBS (without Ca++and Mg++) supplemented with 0.5% bovine serum albumin, stained with specific fluorochrome-conjugated anti-human antibodies or isotype-matched non-specific controls and incubated in the refrigerator 2-8°C for 30 min. After incubation, cells were washed by centrifugation and re-suspended in 0.25-0.5 ml cold PBS.
Cells tested were stained with mouse monoclonal antibodies for CD45-FITC, CD45-PE a pan leukocyte marker, T Cell marker CD3-PE CD8-FITC, T helper cells CD4-FITC, CD8-PE, Natural killer (NK) cell marker CD56-PE, monocyte marker CD31-FITC and B cell marker CD19-PE.
Emission compensation was done by positive control tubes containing cells that were stained with CD45-FITC or CD45-PE; Dead cells were excluded by staining with 7-aminoactinomycin D, only un-stained viable cells were analyzed. At least 10,000 cellular events per sample were analyzed using the CellQuest Pro or FlowJo software. Percentages of isotype control antibody staining, not exceeding 1% stained cells, were used to set the 'positive'staining gates, and were deduced from the specific antibody results. The results are expressed as the percentage of stained cells.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Nechama Sharon, Dr.
- Phone Number: +972-9-8604738
- Email: nsharon@laniado.org.il
Study Locations
-
-
-
Netanya, Israel
- Recruiting
- Sharon Nechama, Laniado Hospital
-
Sub-Investigator:
- Nechama Sharon, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Children aged 0-16
- Have signed a written consent by parents or legal guardians
- Signs and symptoms of flu
Exclusion Criteria:
- Immune system disease
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Influenza A
|
At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR).
Then the different subtypes of lymphocytes were quantified at different stages of the disease.
The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
|
Influenza B
|
At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR).
Then the different subtypes of lymphocytes were quantified at different stages of the disease.
The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantifing the B, T and NK populations of lymphocytes during different stages of the disease caused by Infuenza A H1N1.
Time Frame: 2 years
|
The identification and quantification of the different cell types are performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56. The primary outcome measure was defined as the absolute number of lymphocytes of each sub population. Thus, farther allowing us to follow both absolute numbers and relative percentage of the whole. |
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0015-16-LND
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza A and B
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...University of Minnesota; International Network for Strategic Initiatives in...CompletedInfluenza A | Influenza BUnited States, Australia, Denmark, United Kingdom
-
Ellume Pty LtdCompletedInfluenza A | Influenza BAustralia
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A | Influenza BUnited States
-
Ellume Pty LtdCompletedInfluenza A | Influenza BAustralia
-
Quidel CorporationCompleted
-
Marshfield Clinic Research FoundationUniversity of Wisconsin, Madison; Centers for Disease Control and PreventionCompletedInfluenza A Virus Infection | Influenza B Virus Infection | Immune Response to Influenza VaccineUnited States
-
Sanwa BioTech LimitedChinese University of Hong Kong; Prince of Wales Hospital, Shatin, Hong KongNot yet recruiting
-
SAb Biotherapeutics, Inc.Active, not recruitingInfluenza | Influenza Type B | Influenza Type AUnited States
-
Jiangsu Simcere Pharmaceutical Co., Ltd.CompletedEfficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in ChinaInfluenza A Virus Infection | Influenza B Virus InfectionChina
Clinical Trials on RT-PCR H1N1
-
The University of Hong KongWithdrawn
-
Sher-E-Bangla Medical CollegeRecruitingTo Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19Bangladesh
-
Port Said UniversityUnknownPositive COVID-19 by PCREgypt
-
Ambry GeneticsCrozer-Keystone Health System; St. Joseph Hospital of Orange; The Saratoga HospitalCompleted
-
Centre de l'arthrose, ParisBeaujon HospitalCompleted
-
Oswaldo Cruz FoundationNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust; Walter Reed Army Institute of Research (WRAIR) and other collaboratorsCompleted
-
Versailles HospitalActive, not recruitingSARS-CoV Infection | PinkeyeFrance
-
Assiut UniversityCompleted
-
Centre Hospitalier Sud EssonneUnknown